Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to ClinicGlobeNewsWire · Oct 13, 2026
Gain Therapeutics to Attend the 2026 Maxim Growth SummitGlobeNewsWire · Oct 8, 2026
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months AdministrationGlobeNewsWire · Oct 1, 2026
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement DisordersGlobeNewsWire · Sep 29, 2026
Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head ComparisonDefense World · Sep 28, 2026
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities ConferenceGlobeNewsWire · Sep 17, 2026Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.14 | -$0.11 | Beat |
| May 11, 2026 | -$0.13 | -$0.13 | Beat |
| Mar 26, 2026 | -$0.14 | -$0.11 | Beat |
| Nov 12, 2025 | -$0.15 | -$0.15 | Beat |
| Aug 12, 2025 | -$0.17 | -$0.19 | Miss |
| May 14, 2025 | -$0.16 | -$0.16 | Beat |